Develop personalized neoantigen-based immunotherapies for cancer treatment. Create off-the-shelf immunotherapies targeting shared neoantigens in common solid tumors. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 26% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.9× for every dollar of annual revenue.
Analysts' average target sits 14,403% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $1.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 38 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $138.5M against $1.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.03. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.